Synteract snaps up pediatric CRO KinderPharm for undisclosed price

Children's Hospitals
Synteract acquired specialty pediatric CRO KinderPharm for an undisclosed price, expanding its reach in the pediatrics arena. (GeorgeRudy)

San Diego and North Carolina-based Synteract has acquired specialty pediatric CRO KinderPharm for an undisclosed price.

KinderPharm, which is based in Pennsylvania, focuses on advanced pharmacometric modeling and clinical trial simulation technology as well as providing juvenile formulation and toxicology services.

Financial terms of the deal weren’t disclosed.


Webinar: Optimizing Oncology Trials with a ctDNA Test Custom-Built for MRD and Molecular Monitoring

Join this webinar to discover the advantages of using Signatera™ (RUO), a novel assay custom-designed for each patient that detects circulating tumor DNA (ctDNA) with high sensitivity and specificity to monitor molecular residual disease, early recurrence, and treatment response across solid tumors.

As part of the acquisition, KinderPharm’s founder and chief executive, Martin Graham, Ph.D., becomes senior vice president of pediatric development and global leader for the company’s Center of Pediatric Development. He is being joined by Lynne Georgopoulos, who was named vice president of pediatric development for the Americas. Synteract’s Dr. Martine Dehlinger-Kremer, Ph.D., will support the effort as vice president of pediatric development for Europe.

“We are now integrating Synteract’s existing base of experience and leadership with the focused knowledge and expertise that KinderPharm has provided its clients for many years,” Steve Powell, Synteract’s chief executive, said in a statement. “Together we become the leading CRO for pediatric services, delivery a single source model for preclinical and clinical development, along with the specialized operational and logistical understanding required in working with children and their families.”

Earlier this year, Synteract snapped up specialty contract researcher Cu-Tech for an undisclosed price. That deal was part of Synteract’s move to create a dedicated center for the development of dermatology products and establish itself as a destination for skin-care clinical trials.

Suggested Articles

California data analytics company Saama Technologies has raised $40 million as it looks to bolster its artificial technology platform to “disrupt” clinical…

Thermo Fisher Scientific has moved to acquire viral vector developer and manufacturer Brammer Bio for $1.7 billion in cash.

French biotech AlzProtect has teamed up with CRO Parexel for its midstage test of AZP2006 in patients with progressive supranuclear palsy.